In addition, T cells’ anti-tumor activity and metabolic state is disrupted by the immune-modulatory cytokines present in the TME and the immune checkpoint inhibitors such as PD-1 and CTLA-4 (99, 100). Here, PDCD1 is linked to neoplasm.